Aclaris Therapeutics/$ACRS
1D1W1MYTD1Y5YMAX
Capital at risk
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
- Ticker
- $ACRS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 71
- Headquarters
- Wayne, United States
- Website
- www.aclaristx.com
ACRS Metrics
BasicAdvanced
$892M
-
-$0.59
0.78
-
Price and volume
Market cap
$892M
Beta
0.78
52-week high
$6.60
52-week low
$1.74
Average daily volume
1.9M
Financial strength
Current ratio
3.462
Quick ratio
3.462
Long term debt to equity
1.013
Total debt to equity
1.485
Profitability
EBITDA (TTM)
-85.525
Gross margin (TTM)
-757.70%
Net profit margin (TTM)
-921.50%
Operating margin (TTM)
-1,040.43%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-28.98%
Return on equity (TTM)
-59.10%
Valuation
Price to revenue (TTM)
95.283
Price to book
6.8
Price to tangible book (TTM)
6.8
Price to free cash flow (TTM)
-12.595
Free cash flow yield (TTM)
-7.94%
Free cash flow per share (TTM)
-0.481
Growth
Revenue change (TTM)
-51.05%
Earnings per share change (TTM)
-55.19%
3-year revenue growth (CAGR)
-35.87%
3-year earnings per share growth (CAGR)
-27.76%
10-year earnings per share growth (CAGR)
-14.44%
What the Analysts think about ACRS
Analyst ratings (Buy, Hold, Sell) for Aclaris Therapeutics stock.
Analyst projections of the future price of Aclaris Therapeutics stock.
Bulls say / Bears say
As of June 30, 2026, Aclaris held $170.6 million in cash, cash equivalents and marketable securities and subsequently raised $40.2 million via an ATM share program, providing funding for operations through the end of 2028. (SEC)
Positive full top line results from the Phase 1a SAD/MAD trial of ATI-052 validated a best-in-class PK/PD profile with favorable safety and the potential for up to quarterly dosing, de-risking this key bispecific antibody asset. (SEC)
Enrollment is complete in the Phase 2 trial of bosakitug (ATI-045) for atopic dermatitis, with topline data expected in Q4 2026, offering a near-term catalyst for the antibody franchise. (SEC)
Net loss widened to $21.5 million in Q2 2026 from $15.4 million in Q2 2025, reflecting increased operational losses as development expenses climb. (SEC)
Total revenue fell to $1.6 million in Q2 2026 from $1.8 million a year earlier, underscoring limited near-term commercial traction and reliance on licensing income. (SEC)
Research and development expenses surged to $18.1 million in Q2 2026 from $11.4 million in Q2 2025, highlighting high cash burn and potential dilution risks if key clinical milestones are delayed. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
ACRS Financial Performance
Revenues and expenses
ACRS Earnings Performance
Company profitability
Upcoming events
No upcoming events
ACRS News
AllArticlesVideos
Funds containing ACRS
AllGBPUSDEUR
Fund name | Fund size | $ACRS weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.06% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.